Background : Acid suppressants, especially proton-pump inhibitors, are major contributors to the drug costs in primary care. Although Helicobacter pylori eradication reduces peptic ulcer relapse, some studies suggest that patients may remain symptomatic and continue to require acid-suppressant therapy. Methods : We identified all patients taking long-term acid suppressants in a large primary health care clinic to determine the proportion who had peptic ulcer disease and to examine the effect of H. pylori eradication on their long-term requirement for acid suppressants. Results : 126/394 patients taking long-term acid suppressants had a definite diagnosis of peptic ulcer. Of these 126 patients, 60 were considered appropriate for the study. At Stage 1 (May 1994), all patients were tested for H. pylori infection and positive patients (60/66) received eradication therapy with omeprazole 20 mg bd and amoxycillin (1 gm bd) or clarithromycin (500 mg tds) for 2 weeks. Six weeks later (Stage 2) patients, requirements for continued acid-suppressant treatment were determined and previously positive subjects retested using the 13 C urea breath test. This showed that 70% (42/60) had been successfully eradicated. One year later (Stage 3), 44% (18/41) of the patients successfully eradicated still required acid suppressants. The majority of these patients (11/18; 61%) continued to remain on acid-suppressant treatment at 4 years (Stage 4) (95% CI 38%, 83%). Conclusions : We found that about 1/3 of all patients on long-term acid-suppressant therapy in General Practice had a confirmed diagnosis of peptic ulcer disease. Despite successful eradication treatment for H. pylori at the start of the study, about half of these patients still used acid suppressants after 1 year and 1/4 patients (11/41) in this group continued to remain on acid-suppressant treatment for another 3 years.
[1]
Mulder,et al.
Eradication of Helicobacter pylori does not decrease the long‐term use of acid‐suppressive medication
,
1999,
Alimentary pharmacology & therapeutics.
[2]
M. de Wit,et al.
Helicobacter pylori treatment instead of maintenance therapy for peptic ulcer disease: the effectiveness of case‐finding in general practice
,
1999,
Alimentary pharmacology & therapeutics.
[3]
J. Tijssen,et al.
Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study.
,
1997,
Gastroenterology.
[4]
A. Blum,et al.
Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis.
,
1997,
Gastroenterology.
[5]
A. Axon,et al.
Validation of a rapid whole blood test for diagnosing Helicobacter pylori infection
,
1997,
BMJ.
[6]
A. Price,et al.
The economic and quality-of-life benefits of Helicobacter pylori eradication in chronic duodenal ulcer disease--a community-based study.
,
1995,
Postgraduate medical journal.
[7]
B. Jönsson.
Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease.
,
1996,
Scandinavian journal of gastroenterology. Supplement.